Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MYK-224
BMS-986435 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| BMS-986435 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| MYK-224 | EXPERIMENTAL | - |
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Arm 4 | EXPERIMENTAL | - |
| Arm 1: MYK-224 | EXPERIMENTAL | - |
| Arm 2: MYK-224 + Itraconazole | EXPERIMENTAL | - |
| Arm 3: MYK-224 + Verapamil | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986435 | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
| MYK-224 | DRUG | Specified dose on specified days |
| Itraconazole | DRUG | Specified dose on specified days |
| Verapamil | DRUG | Specified dose on specified days |
Inclusion Criteria \- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability. Exclusion Criteria * Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any...
Top 16 of 30 competitors
BMS-986435 is an investigational small molecule being developed for the treatment of heart failure, specifically heart failure with preserved ejection fraction (HFpEF). It is currently in Phase 2 clinical development and has not been approved for any indication.
BMS-986435 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is the sponsor of the ongoing Phase 2 clinical trial evaluating the drug in patients with heart failure with preserved ejection fraction.
BMS-986435 is in Phase 2 clinical development. One Phase 2 trial is currently active and recruiting has closed, with no completed trials reported. The drug remains investigational and has not received regulatory approval for any indication.
BMS-986435 is being evaluated in a single Phase 2 trial, NCT06122779, titled a study to evaluate safety, tolerability and drug levels of BMS-986435/MYK-224 in participants with heart failure with preserved ejection fraction. The trial is active but not recruiting, with an enrollment of 227 participants across multiple countries.
Yes, BMS-986435 is also known as MYK-224. The ongoing Phase 2 trial refers to the drug as BMS-986435/MYK-224, indicating they are the same investigational compound being developed by Bristol-Myers Squibb for heart failure with preserved ejection fraction.
The molecular target of BMS-986435 has not been disclosed. It is a small molecule in Phase 2 development for heart failure with preserved ejection fraction, but no target or mechanism of action information is available.